2024-05-17 20:36:03 ET
Akoya Biosciences, Inc. (AKYA)
Q1 2024 Earnings Conference Call
May 13, 2024 5:00 PM ET
Company Participants
Priyam Shah - Head, IR
Brian McKelligon - CEO
Johnny Ek - CFO
Conference Call Participants
Kyle Mikson - Canaccord
David Westenberg - Piper Sandler
Mark Massaro - BTIG
Tejas Savant - Morgan Stanley
Subhalaxmi Nambi - Guggenheim
Rachel Vatnsdal - JP Morgan
Mason Carrico - Stephens
Timothy Chiang - Capital One
Presentation
Operator
Good day and thank you for standing by. Welcome to the Akoya Biosciences First Quarter 2024 Earnings Conference Call. All this time all participants are in a listen-only mode. After the speakers’ presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker, Priyam Shah, Head of Investor Relations. Please go ahead.
Priyam Shah
Thank you operator and thank you to everyone who's joining us today on this call. I'm Priyam Shah, Head of Investor Relations at Akoya Biosciences. On the call today, we have Brian McKelligon, Chief Executive Officer; and Johnny Ek, Chief Financial Officer. Earlier today, Akoya released financial results for the first quarter ended March 31, 2024. A copy of the press release is available on the company's website.
Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors.
For a list and description of the risks and uncertainties associated with the Akoya's business, please refer to the risks identified in our filings with the US Securities and Exchange Commission, including in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 5, 2024, and 10-Q filed today May 13, 2024. We urge you to consider these factors and you should be aware that these statements are considered estimates only and are not a guarantee of future performance.
We'll be referring to non-GAAP measures on this call including non-GAAP adjusted gross profit, non-GAAP adjusted gross margin, non-GAAP operating expense and non-GAAP loss from operations. Akoya defines non-GAAP adjusted gross profit as gross profit margin adjusted for certain excesses and obsolete inventory charges. Akoya defines non-GAAP adjusted gross margin as non-GAAP adjusted gross profit divided by total revenue. Akoya defines non-GAAP operating expense as operating expense adjusted for impairment and restructuring charges....
Read the full article on Seeking Alpha
For further details see:
Akoya Biosciences, Inc. (AKYA) Q1 2024 Earnings Call Transcript